Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Fig. 4

Plots of individual responses against 15 tumor associated antigens (TAA) in the Placebo (n = 31) and TG4010 (n = 47) arms expressed as percentage of positive epitope-specific CD8+ T cells before and after treatment. The percentage of patients with onset of a response or an analytically significant amplification of a preexisting response during the treatment course is indicated as a squared figure in each graph. (changes for each individual epitopes were not significant unless otherwise stated, *: p < 0.05, non parametric Mann-Whitney test)

Back to article page